Interpublic Group (IPG) Beats Q2 Earnings & Revenue Estimates
Zacks Investment Research | Jul 21, 2021 03:56AM ET
The Interpublic Group of Companies (NYSE:IPG), Inc. IPG reported better-than-expected second-quarter 2021 results.
Adjusted earnings (excluding 4 cents from non-recurring items) of 70 cents per share beat the Zacks Consensus Estimate by 55.6%. Moreover, the bottom line surged more than 100% on a year-over-year basis.
Net revenues of $2.3 billion beat the consensus estimate by 8.7% and increased 12% on a year-over-year basis. The upside was caused by organic net revenues increase of 19.8% and foreign currency translation was positive 3.1%. Total revenues of $2.51 billion increased 23.6% year over year.
So far this year, shares of Interpublic have gained 33% compared with 8% increase of the industry it belongs to.
Image Source: Zacks Investment Research
Operating income in the quarter came in at $384.4 million, up more than 100% from the prior-year quarter’s figure. Operating margin on net revenues surged to 16.9% from 2.2% in the year-ago quarter. Operating margin on total revenues also increased to 15.3% from 2% in the year-ago quarter.
Adjusted EBITA came in at $405.8 million, up more than 100% from the prior-year quarter. Adjusted EBITA margin on net revenues increased to 17.9% from 9.4% in the year-ago quarter. Adjusted EBITA margin on total revenues rose to 16.2% from 8.6% in the year-ago quarter. Total operating expenses of $2.1 billion increased 7.1% year over year.
h3 Balance Sheet/h3As of Jun 30, 2021, Interpublic had cash and cash equivalents of $2.34 billion compared with $2.02 billion at the end of the prior quarter. Total debt was $3.47 billion compared with $3.45 billion at the end of the prior quarter.
Get The News You Want
During the second quarter, the company paid out a cash dividend of 27 cents per share, amounting to $106.1 million.
Currently, Interpublic sport a Zacks Rank #1 (Strong Buy). You can seeRSG . While Waste Connections will release results on Aug 4, Waste Management and Republic Services will report the same on Jul 27 and Jul 29, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.